Biosimilars Market, 2012 to 2023
Biosimilars Market: By-Drug Class (Monoclonal Antibodies, Recombinant Hormones, Recombinant Growth Factors, Immunomodulators, Anti-Inflammatory Agents, and Others), By Application (Oncology, Blood Disorders, Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Diabetes, and Others), By Manufacturing Type (Captive and Out-sourcing), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Global Biosimilars Market Report Description:
Global biosimilars market report gives a comprehensive outlook on biosimilars products across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on biosimilars market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application, manufacturing type, distribution channel, and geographic regions. This report studies biosimilars market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, biosimilars market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed biosimilars market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the biosimilars market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in manufacturing, supply and prescription of biosimilar products.
Global Biosimilars Market:
Global biosimilars market estimated to be valued US$ 4.10 Bn in 2017 and poised to grow at CAGR of 23.0% over 2017-2023. A market for biosimilars projected to reach US$ 14.23 Bn by 2023 owing to increasing patent expires of biologics and rising biosimilars product pipeline.
Growing demand for cost-effective medications to reduce healthcare burden is driving the market revenue growth
Global biosimilars market is gaining traction in recent times owing to its cost-effective pricing in comparison with patented or branded biologics, which are generally priced higher than biologics. The adoption of cost-effective biosimilars is rising in different healthcare setups across the developed and developing countries to curtail the growing pressure on healthcare budgets. The introduction of biosimilars has even led to improved access to the premium-priced biopharmaceuticals in developing and underdeveloped markets with lesser costs. Moreover, favourable government policies to promote cost-effective biosimilars expected to drive market revenue growth over the forecast period.
Increasing prevalence of several chronic diseases are expected to drive biosimilars market revenue growth over the forecast period
The rising prevalence of several chronic diseases such as cancer, diabetes, cardiovascular diseases, autoimmune disease, and among others across the developed and developing economies expected to drive the market for Biosimilars Market over the forecast period. The growing demand from developing and an underdeveloped market for improved healthcare access are driving the market revenue growth over the forecast period. Moreover, several players are increasing their focus from developed markets to developing markets to tap increasingly growing market opportunity is driving the market revenue growth. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide.
Europe emerged as prominent region for Biosimilars market across the globe
Europe market expected to hold the higher revenue share in global biosimilars market owing to healthcare practitioners shift to low priced drugs, and wider treatment choices available in the region. Asia-pacific biosimilars market projected to grow at highest CAGR over the forecast period in comparison with other regions owing to large out-of-pocket healthcare expenditure and large medical unmet need due to lack of patented product availability.
Competition Assessment
Key players profiled in the global Biosimilars market include:
Amgen Inc. (U.S.)
Biocon Ltd. (India)
Celltrion, Inc. (South Korea)
Dr Reddy’s Laboratories Ltd. (India)
F. Hoffmann-La Roche Ltd. (Switzerland)
Pfizer Inc. (U.S.)
Samsung Bioepis (South Korea)
Novartis AG (Switzerland)
Teva Pharmaceuticals Industries Ltd. (Israel)
Players in biosimilars market are focusing on introducing low-cost biosimilars in developed and developing economies to garner larger market revenue share in global biosimilars market. For instance, in 2015 Sandoz (Novartis AG) launched generic version (Glatopa) of copaxone (glatiramer acetate) in U.S. market.
Global Biosimilars Market Report Description:
Global biosimilars market report gives a comprehensive outlook on biosimilars products across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on biosimilars market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application, manufacturing type, distribution channel, and geographic regions. This report studies biosimilars market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, biosimilars market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed biosimilars market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the biosimilars market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in manufacturing, supply and prescription of biosimilar products.
Global Biosimilars Market:
Global biosimilars market estimated to be valued US$ 4.10 Bn in 2017 and poised to grow at CAGR of 23.0% over 2017-2023. A market for biosimilars projected to reach US$ 14.23 Bn by 2023 owing to increasing patent expires of biologics and rising biosimilars product pipeline.
Growing demand for cost-effective medications to reduce healthcare burden is driving the market revenue growth
Global biosimilars market is gaining traction in recent times owing to its cost-effective pricing in comparison with patented or branded biologics, which are generally priced higher than biologics. The adoption of cost-effective biosimilars is rising in different healthcare setups across the developed and developing countries to curtail the growing pressure on healthcare budgets. The introduction of biosimilars has even led to improved access to the premium-priced biopharmaceuticals in developing and underdeveloped markets with lesser costs. Moreover, favourable government policies to promote cost-effective biosimilars expected to drive market revenue growth over the forecast period.
Increasing prevalence of several chronic diseases are expected to drive biosimilars market revenue growth over the forecast period
The rising prevalence of several chronic diseases such as cancer, diabetes, cardiovascular diseases, autoimmune disease, and among others across the developed and developing economies expected to drive the market for Biosimilars Market over the forecast period. The growing demand from developing and an underdeveloped market for improved healthcare access are driving the market revenue growth over the forecast period. Moreover, several players are increasing their focus from developed markets to developing markets to tap increasingly growing market opportunity is driving the market revenue growth. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide.
Europe emerged as prominent region for Biosimilars market across the globe
Europe market expected to hold the higher revenue share in global biosimilars market owing to healthcare practitioners shift to low priced drugs, and wider treatment choices available in the region. Asia-pacific biosimilars market projected to grow at highest CAGR over the forecast period in comparison with other regions owing to large out-of-pocket healthcare expenditure and large medical unmet need due to lack of patented product availability.
Competition Assessment
Key players profiled in the global Biosimilars market include:
Amgen Inc. (U.S.)
Biocon Ltd. (India)
Celltrion, Inc. (South Korea)
Dr Reddy’s Laboratories Ltd. (India)
F. Hoffmann-La Roche Ltd. (Switzerland)
Pfizer Inc. (U.S.)
Samsung Bioepis (South Korea)
Novartis AG (Switzerland)
Teva Pharmaceuticals Industries Ltd. (Israel)
Players in biosimilars market are focusing on introducing low-cost biosimilars in developed and developing economies to garner larger market revenue share in global biosimilars market. For instance, in 2015 Sandoz (Novartis AG) launched generic version (Glatopa) of copaxone (glatiramer acetate) in U.S. market.
1. EXECUTIVE SUMMARY
2. GLOBAL BIOSIMILARS MARKET INTRODUCTION
2.1. Global Biosimilars Market – Taxonomy
2.2. Global Biosimilars Market –Definitions
2.2.1. Drug Class
2.2.2. Application
2.2.3. Manufacturing Type
2.2.4. Distribution Channel
3. GLOBAL BIOSIMILARS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Biosimilars Market Dynamics – Factors Impact Analysis
3.6. Global Biosimilars Market – Regulations
3.6.1. U.S.
3.6.2. Europe
4. GLOBAL BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL BIOSIMILARS MARKET , BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Monoclonal Antibodies
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Recombinant Hormones
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Recombinant Growth Factors
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Immunomodulators
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Anti-Inflammatory Agents
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. GLOBAL BIOSIMILARS MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Oncology
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Blood Disorders
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Autoimmune Diseases
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Growth Hormone Deficiency
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Infectious Diseases
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Diabetes
6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Others
6.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
7. GLOBAL BIOSIMILARS MARKET FORECAST, BY MANUFACTURING TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Captive
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Out-sourcing
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
8. GLOBAL BIOSIMILARS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9. GLOBAL BIOSIMILARS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. North America
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Region, 2017 – 2023
10. NORTH AMERICA BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Monoclonal Antibodies
10.1.2. Recombinant Hormones
10.1.3. Recombinant Growth Factors
10.1.4. Immunomodulators
10.1.5. Anti-Inflammatory Agents
10.1.6. Others
10.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Oncology
10.2.2. Blood Disorders
10.2.3. Autoimmune Diseases
10.2.4. Growth Hormone Deficiency
10.2.5. Infectious Diseases
10.2.6. Diabetes
10.2.7. Others
10.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Captive
10.3.2. Out-sourcing
10.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023
10.7. North America Biosimilars Market Dynamics – Trends
11. EUROPE BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Monoclonal Antibodies
11.1.2. Recombinant Hormones
11.1.3. Recombinant Growth Factors
11.1.4. Immunomodulators
11.1.5. Anti-Inflammatory Agents
11.1.6. Others
11.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Oncology
11.2.2. Blood Disorders
11.2.3. Autoimmune Diseases
11.2.4. Growth Hormone Deficiency
11.2.5. Infectious Diseases
11.2.6. Diabetes
11.2.7. Others
11.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Captive
11.3.2. Out-sourcing
11.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023
11.7. Europe Biosimilars Market Dynamics – Trends
12. ASIA-PACIFIC BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Monoclonal Antibodies
12.1.2. Recombinant Hormones
12.1.3. Recombinant Growth Factors
12.1.4. Immunomodulators
12.1.5. Anti-Inflammatory Agents
12.1.6. Others
12.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Oncology
12.2.2. Blood Disorders
12.2.3. Autoimmune Diseases
12.2.4. Growth Hormone Deficiency
12.2.5. Infectious Diseases
12.2.6. Diabetes
12.2.7. Others
12.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Captive
12.3.2. Out-sourcing
12.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023
12.7. Asia- Pacific Biosimilars Market Dynamics – Trends
13. LATIN AMERICA BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Monoclonal Antibodies
13.1.2. Recombinant Hormones
13.1.3. Recombinant Growth Factors
13.1.4. Immunomodulators
13.1.5. Anti-Inflammatory Agents
13.1.6. Others
13.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Oncology
13.2.2. Blood Disorders
13.2.3. Autoimmune Diseases
13.2.4. Growth Hormone Deficiency
13.2.5. Infectious Diseases
13.2.6. Diabetes
13.2.7. Others
13.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Captive
13.3.2. Out-sourcing
13.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Venezuela
13.5.5. Rest of Latin America
13.6. Latin America Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023
13.7. Latin America Biosimilars Market Dynamics – Trends
14. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
14.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Monoclonal Antibodies
14.1.2. Recombinant Hormones
14.1.3. Recombinant Growth Factors
14.1.4. Immunomodulators
14.1.5. Anti-Inflammatory Agents
14.1.6. Others
14.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Oncology
14.2.2. Blood Disorders
14.2.3. Autoimmune Diseases
14.2.4. Growth Hormone Deficiency
14.2.5. Infectious Diseases
14.2.6. Diabetes
14.2.7. Others
14.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Captive
14.3.2. Out-sourcing
14.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023
14.7. MEA Biosimilars Market Dynamics – Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Amgen Inc. (U.S.)
15.2.2. Biocon Ltd. (India)
15.2.3. Celltrion, Inc. (South Korea)
15.2.4. Dr Reddy’s Laboratories Ltd. (India)
15.2.5. F. Hoffmann-La Roche Ltd. (Switzerland)
15.2.6. Pfizer Inc. (U.S.)
15.2.7. Samsung Bioepis (South Korea)
15.2.8. Novartis AG (Switzerland)
15.2.9. Teva Pharmaceuticals Industries Ltd. (Israel)
16. RESEARCH METHODOLOGY
17. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL BIOSIMILARS MARKET INTRODUCTION
2.1. Global Biosimilars Market – Taxonomy
2.2. Global Biosimilars Market –Definitions
2.2.1. Drug Class
2.2.2. Application
2.2.3. Manufacturing Type
2.2.4. Distribution Channel
3. GLOBAL BIOSIMILARS MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Biosimilars Market Dynamics – Factors Impact Analysis
3.6. Global Biosimilars Market – Regulations
3.6.1. U.S.
3.6.2. Europe
4. GLOBAL BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL BIOSIMILARS MARKET , BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Monoclonal Antibodies
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Recombinant Hormones
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Recombinant Growth Factors
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Immunomodulators
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Anti-Inflammatory Agents
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. GLOBAL BIOSIMILARS MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Oncology
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Blood Disorders
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Autoimmune Diseases
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Growth Hormone Deficiency
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Infectious Diseases
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Diabetes
6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Others
6.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
7. GLOBAL BIOSIMILARS MARKET FORECAST, BY MANUFACTURING TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Captive
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Out-sourcing
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
8. GLOBAL BIOSIMILARS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9. GLOBAL BIOSIMILARS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. North America
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Region, 2017 – 2023
10. NORTH AMERICA BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Monoclonal Antibodies
10.1.2. Recombinant Hormones
10.1.3. Recombinant Growth Factors
10.1.4. Immunomodulators
10.1.5. Anti-Inflammatory Agents
10.1.6. Others
10.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Oncology
10.2.2. Blood Disorders
10.2.3. Autoimmune Diseases
10.2.4. Growth Hormone Deficiency
10.2.5. Infectious Diseases
10.2.6. Diabetes
10.2.7. Others
10.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Captive
10.3.2. Out-sourcing
10.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023
10.7. North America Biosimilars Market Dynamics – Trends
11. EUROPE BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Monoclonal Antibodies
11.1.2. Recombinant Hormones
11.1.3. Recombinant Growth Factors
11.1.4. Immunomodulators
11.1.5. Anti-Inflammatory Agents
11.1.6. Others
11.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Oncology
11.2.2. Blood Disorders
11.2.3. Autoimmune Diseases
11.2.4. Growth Hormone Deficiency
11.2.5. Infectious Diseases
11.2.6. Diabetes
11.2.7. Others
11.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Captive
11.3.2. Out-sourcing
11.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Poland
11.5.8. Rest of Europe
11.6. Europe Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023
11.7. Europe Biosimilars Market Dynamics – Trends
12. ASIA-PACIFIC BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Monoclonal Antibodies
12.1.2. Recombinant Hormones
12.1.3. Recombinant Growth Factors
12.1.4. Immunomodulators
12.1.5. Anti-Inflammatory Agents
12.1.6. Others
12.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Oncology
12.2.2. Blood Disorders
12.2.3. Autoimmune Diseases
12.2.4. Growth Hormone Deficiency
12.2.5. Infectious Diseases
12.2.6. Diabetes
12.2.7. Others
12.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Captive
12.3.2. Out-sourcing
12.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023
12.7. Asia- Pacific Biosimilars Market Dynamics – Trends
13. LATIN AMERICA BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Monoclonal Antibodies
13.1.2. Recombinant Hormones
13.1.3. Recombinant Growth Factors
13.1.4. Immunomodulators
13.1.5. Anti-Inflammatory Agents
13.1.6. Others
13.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Oncology
13.2.2. Blood Disorders
13.2.3. Autoimmune Diseases
13.2.4. Growth Hormone Deficiency
13.2.5. Infectious Diseases
13.2.6. Diabetes
13.2.7. Others
13.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Captive
13.3.2. Out-sourcing
13.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Venezuela
13.5.5. Rest of Latin America
13.6. Latin America Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023
13.7. Latin America Biosimilars Market Dynamics – Trends
14. MIDDLE EAST AND AFRICA BIOSIMILARS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
14.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Monoclonal Antibodies
14.1.2. Recombinant Hormones
14.1.3. Recombinant Growth Factors
14.1.4. Immunomodulators
14.1.5. Anti-Inflammatory Agents
14.1.6. Others
14.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Oncology
14.2.2. Blood Disorders
14.2.3. Autoimmune Diseases
14.2.4. Growth Hormone Deficiency
14.2.5. Infectious Diseases
14.2.6. Diabetes
14.2.7. Others
14.3. Manufacturing Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Captive
14.3.2. Out-sourcing
14.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Biosimilars Market - Opportunity Analysis Index, By Drug Class, By Application, By Manufacturing Type, By Distribution Channel, and Country, 2017 – 2023
14.7. MEA Biosimilars Market Dynamics – Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Amgen Inc. (U.S.)
15.2.2. Biocon Ltd. (India)
15.2.3. Celltrion, Inc. (South Korea)
15.2.4. Dr Reddy’s Laboratories Ltd. (India)
15.2.5. F. Hoffmann-La Roche Ltd. (Switzerland)
15.2.6. Pfizer Inc. (U.S.)
15.2.7. Samsung Bioepis (South Korea)
15.2.8. Novartis AG (Switzerland)
15.2.9. Teva Pharmaceuticals Industries Ltd. (Israel)
16. RESEARCH METHODOLOGY
17. KEY ASSUMPTIONS AND ACRONYMS
